Interstitial Lung Disease Trial, Recruiting NCT06811389 Sponsor: Weill Medical College of Cornell University Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Interstitial Lung Disease Trial, Recruiting

NCT06811389
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Hypersensitivity Pneumonitis (a lung condition caused by inhaling certain substances) by your doctor.
  • You are 18 years of age or older.
  • You are able to speak and understand English.
  • You are willing to work with a peer coach as part of the study.
  • You own or have regular access to a working smartphone or tablet.
  • You have access to the internet.
  • You currently live in the United States.
  • Your doctor has given verbal approval for you to take part in physical activity or movement goals.
  • Your score on a depression questionnaire (called the PHQ-8) is below 20, meaning you are not experiencing severe depression at this time.

Who may not be able to join:

  • You have not been diagnosed with Hypersensitivity Pneumonitis.
  • You are younger than 18 years old.
  • Your doctor has determined that you have severe difficulties with memory, thinking, or understanding.
  • Your depression questionnaire score (PHQ-8) is 20 or higher, indicating severe depression — the study team will help connect you with other care options.
  • Your medical records show a history of an eating disorder, active substance misuse, thoughts of suicide or harming others, post-traumatic stress disorder (PTSD), or episodes of mania or psychosis.
  • Your doctor has determined that you are severely ill or in very poor health.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kerri I Aronson, MD, Weill Medical College of Cornell University

Phone: (646)962-8130

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 May 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Attrition Rate; Attendance rate; Retention rate; Implementation Survey

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov